Please login to the form below

Not currently logged in
Email:
Password:

Roche's skin cancer drug Zelboraf recommended in EU

CHMP gives positive opinion for drug's use in advanced melanoma

European regulatory advisors have recommended Roche's Zelboraf be approved to treat an advanced form of skin cancer.

The Committee for Medicinal Products for Human Use (CHMP) backed the drug's use as a monotherapy for adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Zelboraf, which Roche co-developed with Daiichi-Sankyo, could improve overall survival in melanoma patients with tumours that are positive for the BRAF V600 mutation, which can lead to increased and uncontrolled cell growth.

Metastatic melanoma is one of the most aggressive forms of skin cancer, with a mortality rate of over 75 per cent during the first year after diagnosis.

There are around 132,000 new melanoma cases a year and it is thought that mutated forms of the BRAF protein are present in half these.

A protein kinase inhibitor, Zelboraf works by inhibiting the mutated enzyme and is taken as a twice-daily pill. It is designed to be used with a diagnostic test developed by Roche to detect the BRAF mutation.

Zelboraf was approved by Food and Drug Administration in August, 2011 in the US, where Roche said the price of the drug would come to around $56,000 for a six-month course of treatment, but no European price details have been announced.

Roche has a number of other marketing applications for Zelboraf under review in countries that include Australia, New Zealand, Brazil, India, Mexico and Canada.

The final European Commission decision on the marketing authorisation of Zelboraf is expected in February 2012.

19th December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics